Core Viewpoint - Jinxin Fertility (01951) experienced a 5.56% increase in stock price, reaching HKD 3.42 per share, with a trading volume of HKD 42.8843 million, indicating positive market sentiment towards the company [1]. Group 1: Company Overview - Jinxin Fertility Medical Group Limited is a leading assisted reproductive service provider in China and the United States, operating multiple hospitals and medical centers [1]. - The company ranked third in the Chinese assisted reproductive services market in 2018, performing 20,958 in vitro fertilization (IVF) cycles, capturing approximately 3.1% market share, and ranked first among non-state-owned assisted reproductive service institutions [1]. Group 2: Financial Performance - As of the 2024 annual report, Jinxin Fertility reported total revenue of CNY 2.812 billion and a net profit of CNY 283 million [2].
锦欣生殖(01951)上涨5.56%，报3.42元/股